Do cost-sharing and entry deregulation curb pharmaceutical innovation?
Related Articles
-
Drugs@FDA Frequently Asked Questions
Pharma Live, , Regulatory Affairs, 0
1. What is the purpose of Drugs@FDA, and what are its main uses? Drugs@FDA allows you to search for...
-
The moving parts of orphan drug development – Courtesy (PMLiVe)
Pharma Live, , Regulatory Affairs, 0
The very mention of orphan drugs is enough to give some pharma accountants the jitters. Chasing a cure for...
-
European Medicines Agency and United States Food and Drug Administration to share manufacturing site inspections
Pharma Live, , Regulatory Affairs, 0
The European Medicines Agency and the United States Food and Drug Administration (FDA) are launching an initiative to share...
-
Frequently Asked Questions: Drug Master File Fee
Pharma Live, , Regulatory Affairs, 0
Q1. What DMFs incur fees? Only DMFs that cover the manufacture of an API (Type II API DMFs) for...
-
-
FDA awards $19m in rare disease grants – Courtesy ( PMLiVe)
Pharma Live, , Regulatory Affairs, 0
The US FDA is to encourage research in rare diseases through 15 grants totalling more than $19m. The regulator...
-
Price regulation in the pharmaceutical industry: Prescription or placebo?
Pharma Live, , Regulatory Affairs, 0
1-s2-0-0167629695000224-mainDownload
-
Indian Pharmacy Practise Regulations 2015 – Courtesy(Pharmabiz.com)
Pharma Live, , Regulatory Affairs, 0
The government of India last January issued a notification entitled Pharmacy Practice Regulations 2015 aimed at enhancing the status...
![](https://ml7mn4k5dnn0.i.optimole.com/w:289/h:289/q:eco/f:best/https://interactivepharm.com/wp-content/uploads/2022/08/Show-your.jpg)